After signing up, you'll start to receive regular news updates from us.
Abbott and Caprion Extend Partnership to Discover Antibody Targets for Cancer
Complete the form below to unlock access to ALL audio articles.
Abbott and Caprion Proteomics have extended their discovery partnership to investigate viable human therapeutic antibody targets for oncology using their CellCarta® technology platform.
The two companies began working together on lung cancer targets three years ago. The extended agreement allows Abbott to retain exclusive rights to 10 targets in lung cancer identified by Caprion for up to two years. Financial terms of the agreement were not disclosed.
"The collaboration with Caprion fits our strategy to extend Abbott's portfolio with novel therapies in areas of high unmet clinical need. From day one, the partnership with Caprion has resulted in a series of potential therapeutic antibody targets for oncology and this extension will provide the additional time required to complete the pre-clinical evaluation of the 10 targets we have selected during the course of our agreement," said Stephen Fesik, divisional vice president, Cancer Research, Abbott.
"We are pleased Abbott has decided to extend our drug discovery collaboration in lung cancer. By combining the strength of Caprion's proteomics discovery platform with Abbott's capabilities in oncology discovery and biologics development, we have demonstrated biological validation of CellCarta's novel target discovery capabilities and are creating a tremendous opportunity to find new therapies for cancer patients," said Martin LeBlanc, president of Caprion Proteomics.
